肺癌免疫治疗的研究进展

Progress in immunotherapy of lung cancer

以程序性细胞死亡受体1(programmed cell death-1,PD-1)及其配体1(programmed death-ligand 1,PD-L1)抑制剂为代表的免疫治疗已经成为肺癌非常重要的治疗手段,在非小细胞肺癌(non-small cell lung cancer,NSCLC)和小细胞肺癌(small cell lung cancer,SCLC)的治疗中均取得了突破性进展,免疫单药、免疫联合化疗、双免疫联合用药相继取得成功,极大改变了肺癌的治疗形式,使肺癌患者实现长期生存,成为肺癌重要的治疗手段。在不断取得突破的同时,针对肺癌免疫治疗领域也在进行着更深层次的研究,包括用药模式的优化、新靶点药物研发、克服耐药策略的探索等,本文将重点介绍肺癌免疫治疗的相关研究进展。

The immunotherapeutic agents programmed cell death-1(PD-1)and programmed death-ligand 1(PD-L1)inhibitors are crucial in lung cancer treatment,enabling breakthroughs in the treatment of both non-small cell lung cancer(NSCLC)and small cell lung cancer(SCLC).Immuno-monotherapy,immunotherapy combined with chemotherapy,and dual immunotherapy have been successful and invaluable in reshaping lung cancer treatment,enabling lung cancer patients to achieve long-term survival.Currently,immunotherapy for lung cancer treatment is the focus of in-depth research,with studies optimizing models for drug use,developing new target drugs,and exploring strategies to overcome drug resistance.This review focuses on the development of immunotherapy for lung cancer treatment.